IP Library Granted Patent US 7,700,550
Granted Patent B2
US 7,700,550 · App. 11/977,429 · Granted Apr 20, 2010

Glycopeptide phosphonate derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,550
App. No.
11/977,429
Granted
Apr 20, 2010
Kind
B2
Abstract

Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

Claims (12)

1. A method for treating a bacterial infection in a human, the method comprising administering to the human a compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is a hydrochloride salt.

3. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is administered intravenously.

4. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is administered once per day.

5. A method for treating a staphylococcal infection in a human, the method comprising administering to the human a compound of the formula:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein the compound is a hydrochloride salt.

7. The method of claim 5 , wherein the compound or a pharmaceutically acceptable salt thereof is administered intravenously.

8. The method of claim 5 , wherein the compound or a pharmaceutically acceptable salt thereof is administered once per day.

9. The method of claim 5 , wherein the staphylococcal infection is caused by Staphylococcus aureus.

10. The method of claim 5 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033181/0646 →